Immunovant, Inc. (IMVT) [Rocket]

In millions, except per share items	Jun-30-23	Dec-31-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21
	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K
Revenues			0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold			0.0	0.0	0.0	0.0	0.0	0.0
Gross profit			0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]			55.0	54.2	49.3	48.3	41.0	39.5
General and administrative			55.0	54.2	49.3	48.3	41.0	39.5
Research and development			111.5	101.8	88.4	79.8	70.4	68.6
Other operating expenses			-2.1	-1.4	-0.5			0.3
EBITDA [+]			-164.2	-154.5	-137.1	-128.3	-111.6	-108.4
EBITDA growth			47.1%	42.6%	36.2%	62.3%	53.8%	64.0%
Depreciation and amortization			0.2	0.2	0.1	0.1	0.1	0.1
EBIT [+]			-164.4	-154.6	-137.2	-128.4	-111.7	-108.4
EBIT growth			47.1%	42.6%	36.3%	62.4%	53.9%	64.1%
Other income (expense), net			-1.9	-2.2	-0.6	-0.2	0.1	0.6
Pre-tax income			-166.3	-156.8	-137.9	-128.6	-111.6	-107.8
Income taxes			0.3	-0.1	-0.2	-0.5	-0.4	-0.4
Tax rate				0.1%	0.1%	0.4%	0.4%	0.3%
Net income			-166.6	-156.7	-137.7	-128.1	-111.2	-107.4

Basic EPS [+]			($1.48)	($1.45)	($1.34)	($1.30)	($1.21)	($1.26)
Growth			22.5%	15.2%	-0.3%	-1.6%	-19.9%	-23.4%
Diluted EPS [+]			($1.48)	($1.45)	($1.34)	($1.30)	($1.21)	($1.26)
Growth			22.5%	15.2%	-0.3%	-1.6%	-19.9%	-23.4%

Shares outstanding (basic) [+]			112.6	107.9	102.5	98.2	92.0	85.2
Growth			22.4%	26.7%	38.3%	64.0%	90.0%	111.2%
Shares outstanding (diluted) [+]			112.6	107.9	102.5	98.2	92.0	85.2
Growth			22.4%	26.7%	38.3%	64.0%	90.0%	111.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.